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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The review aims to determine the effectiveness of written emotional disclosure for people with asthma.
1. To assess the overall efficacy of emotional disclosure compared to emotionally neutral writing in people with asthma on self reported
quality of life.
2. To assess the overall efficacy of emotional disclosure compared to emotionally neutral writing in people with asthma on objective
measures of health outcome.
3. To assess the comparative efficacy of different types of emotional disclosure for people with asthma.
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B A C K G R O U N D
The burden of asthma
Asthma is a chronic inflammatory disease of the airways that is as-
sociated with heightened irritability of the airways and reversible,
episodic airway obstruction (Beasley 2004). Estimates indicate
that asthma currently affects 300 million people worldwide and
that rates of asthma are likely to increase as more communities be-
come urbanised (Beasley 2004). This continued growth will gen-
erate an additional treatment and diagnostic burden for health
care systems. Unfortunately, even if the disease is well controlled,
patients continue to experience residual symptoms that affect their
quality of life. Interventions that are both cheap and complemen-
tary to routine care are therefore needed.
Emotional Disclosure
The emotional disclosure intervention (also known as expressive
writing) was originally developed by Pennebaker and Beall in 1986
(Pennebaker 1986). This is based on the idea that being unable to
share experiences and inhibiting emotions following a stressful or
traumatic event is associated with poorer psychological and phys-
ical health (Pennebaker 1986a). The emotional disclosure inter-
vention asks people to disclose traumatic or stressful experiences
through writing. It has been proposed that emotional disclosure
can have positive effects on both physical and psychological health.
This may occur through the release of inhibition (cathartic effect)
(Pennebaker 1986a; Pennebaker 1993), creation of a coherent nar-
rative (Pennebaker 1993) or through eliciting a stronger sense of
emotional self-regulation (Lepore 2002). Emotional disclosure can
also be conducted orally, however this type of emotional disclosure
may be influenced by different psychological processes and will
be the subject of a separate systematic review. If effective, written
emotional disclosure would provide a cheap and safe adjunct to
pharmacotherapy in routine care.
Existing research syntheses
Several research syntheses have been conducted in the field of ex-
pressive writing (emotional disclosure) with variable results. This
may be because the reviews have either focused specifically on
healthy participants or have compared studies across widely dis-
parate patient groups. The conflicting findings may therefore be
due to the difficulties in comparing the results between studies
conducted across diverse populations.
In a review of 13 studies conducted with healthy participants,
Smyth 1998 revealed that expressive writing significantly en-
hanced physical health, psychological well-being, physiological
functioning and general functioning. A positive effect on physi-
cal health outcomes was also observed in a meta-analysis of nine
studies conducted in people diagnosed with physical or psychi-
atric disorders (Frisina 2004a). In contrast Meads 2005 included
60 studies on both healthy participants as well as those with pre-
existing morbidity, and found no significant difference in health
centre visits between treatment groups. However, Meads 2005 did
not calculate effect sizes if they were not reported in the original
articles, which may have affected the statistical power of the anal-
ysis. Frattaroli 2006 used a comprehensive definition of expres-
sive writing and included 146 trials of healthy participants, trials
including patients with a diverse range of health conditions and
trials in patients who had experienced traumatic events such as
sexual assault. In contrast to earlier meta-analyses (Smyth 1998;
Frisina 2004a), Frattaroli 2006 calculated composite effect sizes
drawn from data extracted from a number of different rating scales
relating to psychological and physical health, and found statisti-
cally significant differences favouring disclosure.
All previous published reviews have explored the effect of written
emotional disclosure on wide populations. The contrasting results
from previous reviews may be due to the different populations
included in the reviews. For example, the clinical populations in-
clude patients with a wide variety of illnesses. As different illnesses
can place different stressors on a person (e.g. the invasiveness of
medical treatment or prognosis). The effects of written emotional
disclosure may be disease specific. The effects of written emotional
disclosure in patients with asthma remains unclear.
Stress is associated with the exacerbation of asthma symptoms
(such as reduced lung function and increased hospital admissions).
The written emotional disclosire intervention aims to reduce the
stress created by inihibiting stressful or traumatic experiences and
may help to help to reduce residual or exacerbations of symptoms
for people with asthma. Two Cochrane systematic reviews (Yorke
2005; Yorke 2006) have focused on the use of psychological inter-
ventions for asthma (one focusing on adults, one focusing on chil-
dren) but neither incorporated the expressive writing paradigm
as a psychological intervention. The psychological approaches in
the 15 studies included in the above reviews consisted of therapies
delivered by a trained therapist such as cognitive behavioural ther-
apy, relaxation techniques and counselling. As expressive writing
is not delivered by a therapist, the expressive writing paradigm was
not included within the scope of these published reviews. This
review will complement existing Cochrane reviews by exploring
the efficacy of expressive writing for people with asthma.
In summary, the existing published reviews of written emotional
disclosure either focus on expressive writing in healthy participants
or across a diverse range of physical and psychological health con-
ditions. This proposal aims to be more specific with regard to both
intervention and outcome by conducting a systematic review on
the effect of emotional disclosure (expressive writing) in asthma.
O B J E C T I V E S
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The review aims to determine the effectiveness of written emo-
tional disclosure for people with asthma.
1.To assess the overall efficacy of emotional disclosure compared to
emotionally neutral writing in people with asthma on self reported
quality of life.
2. To assess the overall efficacy of emotional disclosure compared
to emotionally neutral writing in people with asthma on objective
measures of health outcome.
3. To assess the comparative efficacy of different types of emotional
disclosure for people with asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials assessing the effects of an emotional
writing intervention in subjects with asthma will be included in
the review. Studies including a group of participants randomised
to receive either an emotional disclosure intervention or a control
writing (emotionally neutral) intervention will be reviewed. Only
studies with a neutral writing control group will be included to
ensure that any observed treatment effects are due to the written
emotional disclosure intervention rather than the possibility that
spending time to oneself and writing may in itself be therapeutic
Studiesmay be published in any language.Quasi-randomised trials
will be excluded to minimise bias.
Types of participants
Persons diagnosed with asthma by a general practitioner or consul-
tant or standard guidelines for diagnosis (e.g. British Thoracic So-
ciety, American Thoracic Society). Participants will be both male
and female and of any age. Studies conducted in all settings (in-
cluding hospitals, family practice and in the community) will be
considered to assess the generalisbility of study findings across a
range of situations.
Types of interventions
Emotional disclosure (expressive writing) interventions based on
the protocol developed by Pennebaker et al (Pennebaker 1986)
or the guided disclosure intervention developed by Gidron et al (
Gidron 2002)will be included. The protocol incorporated by each
study will be identified in the study description table included in
the review and considered in the statistical analysis. Studies includ-
ing a control group who receive a non-emotional writing inter-
vention (such as time management) will be included in the review.
Studies including a non-writing control group will be excluded
to control for the potential effect of the writing process itself on
outcomes. The methodological quality of the studies included in
the review will be independently assessed by 2 reviewers. Attempts
will be made to contact the authors of studies for information re-
quired for the review that is not included in the original article.
Types of outcome measures
For the purpose of this review the primary outcome measure will
be lung function, as measured by forced expiratory volume in
1 second (FEV1), peak expiratory flow (PEF) and forced vital
capacity (FVC).
Primary Outcome Measure
1. The primary outcome will be physiological measure of lung
function (e.g. FEV1) as this is used as a clinical measure for asthma
severity.
Secondary Outcome Measures
2. Self reported quality of life using validated questionnaires
3. Self reported symptom scores (e.g. asthma symptom scale)
4. Medication use (e.g. use of bronchodilator)
5. Scheduled or unscheduled health care utilisation (e.g. visits to
hospital, GP practice)
6. Psychological well-being (e.g. depression, anxiety and/or dis-
tress)
Sensitivity analysis
The meta-analaysis will be re-calculated excluding poorer quality
studies and any studies that appear to be outliers from the analysis
to ensure the review results are robust to the method used.
Search methods for identification of studies
Electronic Searches
Trials will be identified from the Cochrane Airways Group Spe-
cialised Register of trials; MEDLINE 1950-present; EMBASE
1974-present; CINAHL1982-present; AMED1985-present; and
PsycINFO 1806-present









8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hyper-
sensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
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15. (atopic$ or atopy).mp.
16. or/1-15





22. ((guid$ or experiment$) adj3 disclos$).mp.
23. or/17-22
24. 16 and 23
This search will be adapted for each database as necessary.
Other sources
Reference lists of all primary studies and review articles will be re-
viewed for additional references. Authors of identified trials will be
contacted and asked to identify other published and unpublished
studies. Experts in the field will also be contacted. The search will
attempt to idenitfy all relevant studies irrespective of language.
Non-English papers will be translated.
Data collection and analysis
Study Selection
Two reviewers (AT and JY) will independently assess the relevance
of abstracts identified by the search against the inclusion criteria.
Full text articles will be obtained for studies potentially fulfilling
the inclusion crieria. The same two review authors will indepen-
dently assess each study against the inclusion criteria using a study
selection form. Any disagreement will be resolved through dis-
cussion to reach a consensus decision. Contact with the original
study investigators will be made if necessary to clarify eligibility.
The reasons for inclusion/exclusion will be recorded on the form
for future reference.
Data Extraction
Data from each study included in the review will be extracted us-
ing a specifically designed form.Data extraction will be completed
independently by two review authors (AT and JY). On completion
the results will be compared and any inconsistencies resolved by
discussison. The review authors will not be blinded to the authors
or the publishing journal of each paper. Aspects of the study de-
sign, participant characteristics, interventions and outcomes will
be described and entered into RevMan 5.
Assessment of the Risk of Bias
To facilitate the assessment of possible risk of bias for each study.
Information will be collected using the Cochrane Collaboration
tool for assessing the risk of bias (Table 8.5.a in the Cochrane
Handbook for Systematic Reviews of Interventions 5.0.0). For
each domain on the tool the procedures undertaken for each study
will be described including verbatim quotes. A judgement as to
the possible risk of bias on each of the six domains will be made
from the extracted infromation with the answer ’yes’ indiating
a low risk of bias and the answer ’no’ indicating a high risk of
bias. If there is insufficient detail reported in the study a judge-
ment ’unclear’ will be made and the original study investigators
will be contacted for more information. These judgement will be
based on the criteria for judging the risk of bias (Table 8.5.c in
the Cochrane Handbook for Systematic Reviews of Interventions
5.0.0). Graphic representations of potential bias within and across
studies will be computed using RevMan 5. Funnel plots will be
used to assess possible publication bias.
Data Synthesis
Extracted data from each study will be entered into a summary
table to enable comparison of study characteristics, quality and
results. Analysis will be performed using RevMan 5 Analyses soft-
ware.
For continuous data, end point FEV1 scores will be expressed as
weighted mean differences with their associated 95% confidence
intervals. The weighted mean difference will be reported for end
point scores on self reported asthma quality of life outcome mea-
sures (such as the AsthmaQuality of LifeQuestionnaire by Juniper
et al (Juniper 1992) and the Asthma Quality of Life Question-
naire by Marks (Marks 1992). Symptom scores and psychological
wellbeing scores will be reported using the standardised mean dif-
ference to combine data from different self report scales.
For dichotomous data, the number of participants with each out-
come event will be entered into a 2x2 contingency table and the
fixed effect odds ratio (OR) with 95% confidence intervals will be
reported.
Heterogeneity of the trials will be assessed by visual inspection
of forest plots and assessed by calculation of the Q statistic and
Cochrane’s I2. If heterogeniety is found potential resasons for the
heterogeniety will be explored. If a high degree of heterogeniety
is found the review will be completed without statsitical meta-
analysis of the results
The following subgroup analyses are proposed:
1. Comparison between severity of asthma (as defined by FEV1
baseline reading). To explore if the effectiveness of the written
emtional intervention is affected by severity of asthma.
2. Comparison between children (aged under 16) and adults. To
explore if the effectiveness of the written emtional intervention is
affected by length of life and writing experience..
3. Self reported quality of life at 1 month, 3 month and 6 month
intervals. This will be conducted to see if treament effects change
over time.
A C K N OW L E D G E M E N T S
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